Kalaris Therapeutics, Inc. (KLRS)

NASDAQ: KLRS · Real-Time Price · USD
2.960
+0.060 (2.07%)
At close: May 29, 2025, 4:00 PM
2.510
-0.450 (-15.20%)
Pre-market: May 30, 2025, 4:00 AM EDT
2.07%
Market Cap 55.36M
Revenue (ttm) n/a
Net Income (ttm) -75.96M
Shares Out 18.70M
EPS (ttm) -10.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,264
Open 2.800
Previous Close 2.900
Day's Range 2.800 - 3.041
52-Week Range 2.645 - 24.150
Beta n/a
Analysts Buy
Price Target n/a
Earnings Date May 14, 2025

About KLRS

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 14
Stock Exchange NASDAQ
Ticker Symbol KLRS
Full Company Profile

Financial Performance

Financial Statements

News

Kalaris to Participate at Stifel Ophthalmology Forum

PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...

6 days ago - GlobeNewsWire

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovasc...

15 days ago - GlobeNewsWire

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving i...

7 weeks ago - GlobeNewsWire

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis...

Other symbols: ALVR
2 months ago - GlobeNewsWire